High sensitivity dPCR and NGS platforms are able to pick up circulating tumor RAS mutations and other molecular alterations in plasma that drive primary or acquired resistance during anti-epidermal growth factor receptor (EGFR) treatment [8, 9]. The gene discussed is EGFR; the disease is neoplasm.